A retrospective comparison of the dose ratio between subcutaneous and oral ketamine [2]

Journal of Pain and Symptom Management

Volumn 25, Issue 5, 2003, Pages 400-402

  Benítez Rosario, Miguel Angel ^a   Feria, Manuel ^b   Salinas Martín, Antonio ^a   Martínez Castillo, Luis Pedro ^a   Martín Ortega, José Javier ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DEXAMETHASONE; DIAZEPAM; GABAPENTIN; HALOPERIDOL; KETAMINE; LAMOTRIGINE; METHADONE; MIDAZOLAM; MORPHINE; TOPIRAMATE;

ADULT; ALLODYNIA; AMYOTROPHIC LATERAL SCLEROSIS; BONE PAIN; CASE REPORT; CLINICAL FEATURE; COLON CANCER; DISEASE COURSE; DYSESTHESIA; HUMAN; HYPERALGESIA; LETTER; MALE; NERVE BLOCK; NEUROPATHIC PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPINE METASTASIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANALGESICS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PAIN; RETROSPECTIVE STUDIES;

EID: 0242586106     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(03)00072-1     Document Type: Letter

References (10)

1. Finlay I. Ketamine and its role in cancer pain. Pain Reviews. 6:1999;303-313.
2. Ohima E., Tei K., Kayazawa H., Urabe N. Continuous subcutaneous injection of ketamine for cancer pain. Can J Anaesth. 37:1990;385-392.
3. Mercadante S. Ketamine in cancer pain. an update Palliat Med. 10:1996;225-230.
4. Fisher K., Coderre T.J., Hagen N.A. Targeting the N-methyl-D-aspartate receptor for chronic pain management. preclinical animal studies, recent clinical experience and future research directions J Pain Symptom Manage. 20:2000;358-373.
5. Grant I.S., Nimmo W.S., Clements J.A. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth. 53:1981;805-809.
6. Yanagihara Y., Ohtani M., Kariya S.et al. Stereoselective high-performance liquid chromatographic determination of ketamine and its active metabolite, norketamine, in human plasma. J Chromatogra B. 746:2000;227-231.
7. Shimoyama M., Shimoyama N., Gorman A.L., Elliott K.J., Inturrisi C.E. Oral ketamine is antinociceptive in the rat formalin test. role of the metabolite, norketamine Pain. 81:1999;85-93.
8. Raben T., Skjelbred P., Øye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther. 289:1999;1060-1066.
9. Enarson M.C., Hays H., Woodroffe M.A. Clinical experience with oral ketamine. J Pain Symptom Manage. 17:1999;384-386.
10. Fitzgibbon E.J., Hall P., Schroder C., Seely J. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes. a strategy for conversion from parenteral to oral ketamine J Pain Symptom Manage. 23:2002;165-170.